<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081753</url>
  </required_header>
  <id_info>
    <org_study_id>1464778</org_study_id>
    <nct_id>NCT04081753</nct_id>
  </id_info>
  <brief_title>Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy</brief_title>
  <acronym>REMEDY</acronym>
  <official_title>Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Georgia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Febrile neutropenic patients are at high risk for developing sepsis and other infections
      which often necessitates acute admission to the Intensive Care Unit (ICU) and are associated
      with high mortality. Neutropenic fever is a medical emergency and early detection of fever
      allows for prompt infectious work up. In this study, the investigators will collect pilot
      data from outpatients utilizing a remote outpatient continuous temperature monitoring device
      to compare the incidence of ICU admission and severe sepsis to historical data for prior
      patients who did not receive at home monitoring device.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Interventional group will be compared with historic group of patients</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change ICU admission</measure>
    <time_frame>1 month</time_frame>
    <description>The interventional group will have less number of ICU admission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change incidence of sepsis in interventional group</measure>
    <time_frame>1 month</time_frame>
    <description>The interventional group will have chnaged rate of sepsis incidence</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>TMD Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temperature Monitoring Device Group - The interventional group, who will be given the temperature monitoring device and will be monitored remotely.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Historic cohort Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Historic cohort group will be enrolled from medical record</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Remote monitoring of temperature</intervention_name>
    <description>The patient will be set up with a remote monitoring device for temperature recording and the temperature will monitored remotely</description>
    <arm_group_label>TMD Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who have acute myeloid leukemia (AML) and are candidates for consolidation
        chemotherapy with high dose cytarabine (HiDAC) after successful remission induction
        chemotherapy

          -  Both male and female

          -  Age 18 years and older

        Exclusion Criteria:

        Patients who have already developed febrile neutropenia during their hospitalization for
        their consolidative cycle of chemotherapy will not be eligible for monitoring for that
        cycle; however, these patients will be able to participate in subsequent cycle if they do
        not develop febrile neutropenia during their subsequent HiDAC hospitalization.

        â€¢ If a patient is admitted to the hospital between cycles of chemotherapy for reasons other
        than febrile neutropenia or its sequelae, they will be taken off study for that cycle and
        data not collected while they are admitted
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Locke J. Bryan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augusta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammad Mian, MBBS, PhD</last_name>
    <phone>706-723-0110</phone>
    <email>MMIAN@augusta.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Mian, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pathak R, Giri S, Aryal MR, Karmacharya P, Bhatt VR, Martin MG. Mortality, length of stay, and health care costs of febrile neutropenia-related hospitalizations among patients with breast cancer in the United States. Support Care Cancer. 2015 Mar;23(3):615-7. doi: 10.1007/s00520-014-2553-0. Epub 2015 Jan 4.</citation>
    <PMID>25556610</PMID>
  </reference>
  <reference>
    <citation>Saini L, Rostein C, Atenafu EG, Brandwein JM. Ambulatory consolidation chemotherapy for acute myeloid leukemia with antibacterial prophylaxis is associated with frequent bacteremia and the emergence of fluoroquinolone resistant E. Coli. BMC Infect Dis. 2013 Jun 22;13:284. doi: 10.1186/1471-2334-13-284.</citation>
    <PMID>23800256</PMID>
  </reference>
  <reference>
    <citation>van Vliet M, Donnelly JP, Potting CM, Blijlevens NM. Continuous non-invasive monitoring of the skin temperature of HSCT recipients. Support Care Cancer. 2010 Jan;18(1):37-42. doi: 10.1007/s00520-009-0627-1. Epub 2009 Apr 25.</citation>
    <PMID>19396473</PMID>
  </reference>
  <reference>
    <citation>Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011 Feb 15;52(4):e56-93. doi: 10.1093/cid/cir073.</citation>
    <PMID>21258094</PMID>
  </reference>
  <reference>
    <citation>Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K, Strasfeld L, Flowers CR. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018 May 10;36(14):1443-1453. doi: 10.1200/JCO.2017.77.6211. Epub 2018 Feb 20.</citation>
    <PMID>29461916</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HiDAC</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Fever</keyword>
  <keyword>AML</keyword>
  <keyword>Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This study result will be used for service improvement of patient of the Augusta University Medical Center</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

